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In most complex diseases, much of the heritability remains unaccounted for by common variants. It has been postulated that lower-
frequency variants contribute to the remaining heritability. Here, we describe a method to test for polygenic inheritance from lower-
frequency variants by using GWAS summary association statistics. We explored scenarios with many causal low-frequency variants
and showed that there is more power to detect risk variants than to detect protective variants, resulting in an increase in the ratio of
detected risk to protective variants (R/P ratio). Such an excess can also occur if risk variants are present and kept at lower frequencies
because of negative selection. The R/P ratio can be falsely elevated because of reasons unrelated to polygenic inheritance, such as uneven
sample sizes or asymmetric population stratification, so precautions to correct for these confounders are essential. We tested our method
on published GWAS results and observed a strong signal in some diseases (schizophrenia and type 2 diabetes) but not others. We also
explored the shared genetic component in overlapping phenotypes related to inflammatory bowel disease (Crohn disease [CD] and
ulcerative colitis [UC]) and diabetic nephropathy (macroalbuminuria and end-stage renal disease [ESRD]). Although the signal was still
present when both CD and UC were jointly analyzed, the signal was lost when macroalbuminuria and ESRD were jointly analyzed, sug-
gesting that these phenotypes should best be studied separately. Thus, our method may also help guide the design of future genetic
studies of various traits and diseases.Introduction
Most common diseases involve a mix of both genetic and
environmental factors and do not follow simple patterns
of Mendelian inheritance. In such diseases, the genetic
component is usually polygenic: genetic variation in
many genes individually contribute a small or a moderate
component of disease risk.1 Genome-wide association
studies (GWASs) have identified numerous genomic loci
in which common variants (R5% frequency) are associ-
ated with complex diseases.2 Even in some of the largest
and most successful GWASs to date, much of the genetic
contribution to phenotype remains unexplained (some-
times called ‘‘missing heritability’’),3,4 suggesting that
lower-frequency variants, not well surveyed by GWASs,
may also contribute to the missing heritability. Indeed,
in some diseases such as autism spectrum disorders (ASD
[MIM 209850]), inherited rare (<1% frequency) and low-
frequency (<5% frequency) variants have been recently
shown to play an important role in the genetic architecture
of the disorder,5,6 suggesting that more loci with low-
frequency variants could be identified if appropriate addi-
tional studies were performed. In other diseases, there is
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low-frequency variation will be fruitful for those diseases.
The relative success of different approaches in identi-
fying more contributing loci will depend on what type
of variation accounts for the missing heritability. Low-
frequency variants might remain undetected because
they might not be well represented or well tagged by
markers on genotyping arrays and therefore would not
be well imputed.7 Along these lines, the statistical power
to detect low-frequency variants in GWASs is much lower
than that of common variants if their underlying effect
sizes are similar.8 Knowing whether low-frequency variants
contribute to the missing heritability of a disease is impor-
tant because approaches better suited to identify addi-
tional common variants differ from those aimed at identi-
fying rarer variants (genotyping arrays with common
variants compared to arrays with lower-frequency variants
or sequencing).
Methods for detecting a contribution from common
variants to the missing heritability have been described
previously. In a GWAS of schizophrenia (SCZ [MIM
181500]),9 Purcell and colleagues developed the concept
of a polygenic score by combining the effects of multiple
common variants that are modestly associated withogram inMedical and Population Genetics, Broad Institute, Cambridge, MA
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schizophrenia. They showed that the score is predictive of
schizophrenia in an independent cohort, thus indicating
that there is a polygenic signal from many yet-to-be-
detected common variants in schizophrenia. Yang and
colleagues adopted a different approach by assessing the
narrow-sense heritability of human height with a linear-
model analysis by using hundreds of thousands of
common variants.10 They found that at least 45% of the
variance of height can be accounted for by common vari-
ants, indicating that there are many common variants
associated with height that have yet to be discovered.
Although both methods can be used to detect a signal of
polygenic inheritance from common variants in complex
diseases, these tests were not designed to specifically test
for low-frequency variants and also require individual-
level genotype data.
In this manuscript, we describe an approach that can
be applied directly to GWAS summary statistics to ascer-
tain the presence of polygenic inheritance from low-
frequency variants. We observed that, if low-frequency
variants contribute to disease susceptibility, there can
be an excess of associated risk variants compared to pro-
tective variants at a given significance level. Here, risk
variants are defined as variants for which the minor allele
is associated with increased risk of disease and protective
variants are defined as those for which the minor allele is
associated with decreased risk of disease. Under the null
model, there should be no excess of associated risk vari-
ants compared to protective variants. We calculated the
risk to protective ratio (R/P ratio) (the ratio of the number
of detected risk variants over the number of detected
protective variants) to test for such an excess of risk
variants. We explored various scenarios that could give
rise to an increase in the R/P ratio. First, we showed
empirically and analytically that when low-allele-
frequency variants contribute to polygenic inheritance
of a disease with low prevalence, there is an elevated
R/P ratio because of greater power to detect risk variants
than protective variants. Next, we showed through simu-
lations that under a scenario of polygenic inheritance
that includes negative selection, risk variants can have
lower average frequencies than protective variants, lead-
ing to an elevated R/P ratio within the lower-frequency
range. However, we also showed that such an elevated
R/P ratio can occur because of reasons unrelated to poly-
genic inheritance. First, we showed that an uneven sam-
ple size (a substantially larger control group than case
group) can produce an apparent increase in the R/P ratio
and therefore, where the sample size is not balanced
between the case and control groups, one should
compare the observed R/P ratio against that obtained
through simulations with the same sized groups of cases
and controls. Next, we showed that particular scenarios
of asymmetric population stratification can produce a
similar excess of low-frequency risk variants and recom-
mend that precautions for detecting and correcting for
such stratification should be performed before one can438 The American Journal of Human Genetics 94, 437–452, March 6confidently interpret an excess of risk variants as being
a signal of polygenic inheritance.
We then applied our method to results from published
GWASs for several diseases, including schizophrenia,11
bipolar disorder (BIP [MIM 125480]),12 major depressive
disorder (MDD [MIM 608516]),13 type 2 diabetes (T2D
[MIM 125853]),14 and various classes of obesity (OB
[MIM 601665]).15 We observed strong signals of increased
risk variants in several of the diseases but little or no signal
in others, suggesting that efforts to discover low-frequency
and rare variants will be more fruitful for the diseases with
such a signal. We further used our method to test whether
apparently related phenotypes share low-frequency or rare
genetic contributors and hence should be analyzed
together or separately. By applying the method to pheno-
types related to diabetic nephropathy (DN [MIM
603933])16 and inflammatory bowel disease (IBD [MIM
266600]),17 we found that the polygenic signal was elimi-
nated when individuals with macroalbuminuria and
individuals with end-stage renal disease were analyzed
together, whereas we still observed a significant signal
when individuals with Crohn disease and ulcerative colitis
were analyzed together. Thus, our method has the poten-
tial to guide the strategy in searching for additional genetic
loci as well as in prioritizing the choice of phenotype for
future studies of rare genetic variation in polygenic traits
and diseases.Material and Methods
Testing for an Excess of Risk Variants from GWAS
Summary Statistics
Calculating the R/P Ratio Statistic from Observed GWAS Summary
Statistics
The four input fields we used for R/P ratio calculations for each
SNP are as follows: an identifier (rsID), the minor allele frequency,
the association p value, and a field to determine the direction of
effect, i.e., either an odds-ratio (OR) or an effect size (b). The ORs
or bs were adjusted to reflect the effect of the minor allele by
inverting the ORs or changing the sign of the bs if they were
reported for the major allele. Each variant was assigned as risk if
the OR > 1 or b > 0 and protective if the OR < 1 or b < 0. Neutral
variants, i.e. OR ¼ 1 or b ¼ 0 were discarded from the analysis. We
removed SNPs not present in the HapMap CEU population (phase
2, release 28),18,19 not in the 1000 Genomes EUR population,20 or
withminor allele frequency less than 1%.We sorted the remaining
variants in order frommost significant to least and performed LD-
pruning by systematically going through the variants and
removing variants that have an r2 > 0.1 with any of the more
significantly associated variants. We used PLINK21 to calculate r2
correlations of variant pairs within a 1 megabase window from
379 EUR individuals of the 1000 Genomes. To measure the excess
of risk variants in the lower-frequency range, we separated the
low-frequency variants into three distinct bins, i.e., 1%–5%, 5%–
10%, and 10%–15%.We also included the 30%–50%bin as a nega-
tive control, where we should not observe any excess of risk
variants. For each bin, we counted the number of detected risk var-
iants and the number of detected protective variants that meet, 2014
significance cutoffs of p < 0.001 and p < 0.01. We calculated the
R/P ratio as
R=P ratio ¼ No: of detected risk variants
No: of detected protective variants
:
Assessing the Significance of the Observed R/P Ratio
To assess the significance of an elevation in R/P ratio, we simulated
individuals with HAPGEN22 by using parameters from the
HapMap CEU population (phase 3, release 2) to obtain the null
distribution of the log2 R/P ratio statistic. We first simulated
100,000 individuals to form a pool of individuals that we could
subsequently sample from. Next, we randomly sampled the
same number of individuals in the case and control groups as
were used in the actual GWAS, performed the association test
with PLINK, with LD-pruning and R/P ratio calculations identical
to the procedure described above. We repeated this process 1,000
times to obtain accurate estimates of the sample mean (m) and
standard deviation (s) of the log2 R/P ratio under the null for
each of our frequency bins and p value cutoffs. We calculated
the significance of the observed log2 R/P ratio by performing a
one-tailed Z test to obtain the Z score and p value (p), i.e.,
Z score ¼ observed log2R=P ratio m
s
p ¼
ZN
Zscore
Nðx;0;1Þdx:
We defined p < 0.01 as our significance threshold for calling a
significant excess of risk variants. We used the log2 R/P ratio as
our test statistic because the log2 R/P ratio is normally distributed
for all the frequency bins and p value cutoffs used (Figure S1 avail-
able online).Calculating Noncentrality Parameter for Comparing
Power between Risk and Protective Variants
Power Calculation
The power of a variant is expressed by calculating the expected
noncentrality parameter (NCP) of the c2 distribution for the alter-
native distribution. The greater the NCP, the more power there is
to detect the effective variant. The algorithm for calculating NCP
is identical to the genetic power calculator8 for case-control
threshold-selected quantitative traits, assuming an additive model
of the QTL effect, i.e., the dominance to additive QTL effect
parameter is set to 0. The variance explained for a SNP with allele
frequency as p and effect size as b is b22p(1  p). For risk variants,
we calculated the NCP (NCPrisk) for multiple values of effect sizes
(b), ranging from 0 to 0.5 with intervals of 0.01. Similarly, for pro-
tective variants, we calculated the NCP (NCPprotective) for multiple
values of b, ranging from 0 to0.5 with intervals of 0.01. The rela-
tive difference in power between risk and protective variants is
measured by the NCP ratio. The NCP ratio is calculated as
NCP ratio ¼ NCPrisk
NCPprotective
:
Base Model
We define the base model as a set of parameters used for calcu-
lating NCP: 10,000 case subjects, 10,000 control subjects, and
effective and marker variant frequency set to 1%. The prevalenceThe Ameis set as 1%, i.e., the trait threshold’s lower and upper limit is
2.33 and 9, respectively, for case subjects and 9 and 2.33 for
control subjects. We have used 9 and 9 as surrogates for infinity
(þN and -N, respectively), but any sufficiently large number will
not change the conclusions of the downstream analyses. Com-
plete linkage disequilibrium (LD) between the causal variant and
marker variant is assumed, i.e., D0 ¼ 1.Simulating R/P Ratios for Negative Selection
Obtaining Frequencies and Effect Sizes
If the variants that have an effect on the phenotype are under
negative selection, it can lead to scenarios where there are more
risk variants than protective variants to begin with, especially for
low-frequency variants. To illustrate this, we simulated neutral
variants and causal variants under negative selection by using
previously published models and parameters that result in an
allele spectrum similar to that observed in the European popula-
tion.23,24 We used the forward simulation package ForSim25 to
simulate coding sequence variation in the European population
in 1,000 genes. The average gene coding length was set as
1,500 bp. We used a mutation rate per site of 2 3 108 and a uni-
form locus-wide recombination rate of 2 Mb/cM. We modeled the
distribution of selection coefficients (s) for de novo missense
mutations by a gamma distribution.26 We used the conventional
4-parameter model of the history of the European population
with long-term constant size (N ¼ 8,100 for 45,000 generations)
followed by a bottleneck (N ¼ 2,000) and then by exponential
growth (1.5% increase per generation for 370 generations) to
achieve a final population size of approximately 500,000 individ-
uals.23,24 We obtained 823 nonneutral variants that have minor
allele frequencies R1% and assigned them as effective variants
and assuming that the allele under negative selection confers
risk, i.e., positive effect (Figure S2). By considering only additive
genetic effects, we assigned effect sizes as b ¼ st(1þ ε) as suggested
in Eyre-Walker.27 Here, b is the variant’s additive effect on the
quantitative trait, s is the absolute value of the variant’s selection
coefficient, ε is a normally distributed random noise parameter
that was set to having mean 0 and standard deviation 0.05, and
t is the degree of coupling between b and s and was set at 0.5 for
our analyses. The effect sizes are scaled so that these 823 variants
explain 60% of the phenotypic variance.
Obtaining Phenotypes and Calculating R/P Ratio for the Selection Model
We use the 100,000 HAPGEN-simulated individuals and selected
823 matched SNPs such that the frequency matches the variants
generated by ForSim. We then assigned these matched SNPs
with effect sizes determined earlier. We calculated the phenotypic
Z score for each of our 100,000 individuals in the same way that
we did previously,28 i.e., by calculating the weighted allele score
(WAS) and adding it to a randomly generated variable sampled
from a normal distribution of mean 0 and variance 0.4 such
that the total variance explained is 1. We then sampled 2,000
individuals with phenotypic Z scores > 1.645 (5% prevalence) as
case subjects and another 2,000 individuals with phenotypic
Z scores % 1.645 as control subjects. We used PLINK to perform
the association test on all the variants and calculated the R/P ratio
within the same frequency bins as well as p value cutoffs as
described above. This process was repeated 1,000 times to obtain
the distribution of the R/P ratio. For the control model, we
randomly sampled 2,000 individuals as case subjects and 2,000
individuals as control subjects and calculated the R/P ratio as
described above.rican Journal of Human Genetics 94, 437–452, March 6, 2014 439
Simulating R/P Ratios for Population Stratification
We use HAPGEN to simulate 4,000 distinct individuals from the
HapMap CEU population (phase 3, release 2) as well as another
4,000 distinct individuals from the HapMap TSI population (phase
3, release 2). For complete stratification, we randomly sampled
1,000 individuals from the CEU pool as control subjects and
1,000 individuals from the TSI pool as case subjects. We simulated
asymmetric mixtures of 1%, 5%, and 10% by randomly sampling
1,000 individuals from the CEU pool as control subjects and sam-
pling 10, 50, and 100 individuals from the TSI pool as case sub-
jects, respectively, and made up the remainder of the case group
from the CEU pool. We used PLINK to perform the association
test on all the variants and calculated the R/P ratio within the
same frequency bins as well as p value cutoffs as described above.
Each process was repeated 1,000 times to obtain the distribution of
the R/P ratio. All PCA analysis was performed with smartpca
from the EIGENSOFT 3.0 package.29 All meta-analysis of GWAS
summary statistics were performed with METAL.30 Inflation of
the GWAS test statistic because of population stratification was
assessed by genomic control inflation factor (lGC).
31Calculating R/P Ratio from Published GWAS
Summary Statistics
Schizophrenia, Major Depressive Disorder, and Bipolar Disorder
GWAS summary statistics were provided from published results
of schizophrenia,11 bipolar disorder,12 and major depressive dis-
order.13 SNPs that failed imputation (INFO < 0.6) were discarded.
The sizes of the case and control groups used for simulating the
null distribution are as follows: schizophrenia (SCZ), 9,394 case
subjects and 12,462 control subjects; major depressive disorder
(MDD), 9,240 case subjects and 9,519 control subjects; and bipolar
disorder (BIP), 7,481 case subjects and 9,250 control subjects.
Type 2 Diabetes
GWAS summary statistics were provided from published results of
type 2 diabetes.14 SNPs that passed imputation for fewer than
15,000 individuals (Ncases < 15,000) were discarded. A total of
15,000 case subjects and 50,337 control subjects were used for
simulating the null distribution.
Obesity
GWAS summary statistics were provided from published results of
various classes of obesity.15 SNPs that passed imputation for fewer
than 50,000 individuals (Ncases < 50,000), 10,000 individuals
(Ncases < 10,000), 2,000 individuals (Ncases < 2,000), and 1,000
individuals (Ncases < 1,000) were discarded for the overweight
(BMI > 25), class 1 (BMI > 30), class 2 (BMI > 35), and class 3
(BMI > 40) data sets, respectively. The sizes of the case and control
groups used for simulating the null distribution are as follows:
overweight, 50,000 case subjects and 35,715 control subjects; class
1, 10,000 case subjects and 20,325 control subjects; class 2, 2,000
case subjects and 12,466 control subjects; and class 3, 1,000 case
subjects and 18,346 control subjects.
Inflammatory Bowel Disease
GWAS summary statistics were provided from published results of
Crohn disease (CD),32 ulcerative colitis (UC),33 and the combined
case cohort of both Crohn disease and ulcerative colitis
(CDþUC).17 SNPs that failed imputation (INFO < 0.6) were dis-
carded. The sizes of the case and control groups used for simu-
lating the null distribution are as follows: CD, 5,956 case subjects
and 14,927 control subjects; UC, 6,968 case subjects and 20,464
control subjects; and CDþUC, 12,882 case subjects and 21,770
control subjects.440 The American Journal of Human Genetics 94, 437–452, March 6Diabetic Nephropathy
GWAS summary statistics were provided from published results of
phenotypes related to diabetic nephropathy16 that are macroalbu-
minuria (MACRO) and end-stage renal disease (ESRD). SNPs that
failed imputation in at least 1 cohort were discarded. The sizes of
the case and control groups used for simulating the null distribu-
tion are as follows: macroalbuminuria versus control (MACROctrl),
1,478 case subjects and 3,315 control subjects; end-stage renal
disease versus control (ESRDctrl), 1,399 case subjects and 3,315
control subjects; ESRD versus controls that include MACRO
(ESRDctrlþmacro), 1,399 case subjects and 5,253 control subjects;
and combined MACRO and ESRD versus control ([MACRO þ
ESRD]ctrl), 2,916 case subjects and 3,315 control subjects.Results
We developed a method to detect and assess the signifi-
cance of an excess of risk variants, measured by the ratio
of risk variants to protective variants (R/P ratio) within a
series of frequency bins and p value cutoffs (see Material
and Methods). We proceeded to show that under an
assumption of polygenic inheritance from low-frequency
variants, there is more statistical power to detect risk vari-
ants than to detect protective variants, which can result
in an increased R/P ratio. We also showed that such an
excess can also occur if risk variants are kept at lower fre-
quencies because of negative selection. However, such an
excess can also occur because of reasons unrelated to a
contribution of rare variants to disease risk: uneven sample
sizes or asymmetric population stratification. Therefore,
steps have to be taken to account for these latter possibil-
ities before one can confidently interpret the excess of
risk variants as a true signal of polygenic inheritance.
Finally, we applied the method to GWAS summary statis-
tics from several published studies.Significantly Higher Power to Detect Low-Frequency
Risk Variants of Moderate to Large Effect
The liability threshold model for disease34 has been shown
to be consistent with results from GWASs for multiple
diseases.35 This model assumes that there is an underlying
unmeasured trait related to disease risk and that individ-
uals are affected with disease only when the value of the
trait exceeds a particular threshold. Under such a model,
we discovered that the statistical power to detect risk
variants is higher than the power to detect protective
variants, even when they have the same effect size with
respect to the underlying unmeasured trait. For example,
we calculated power by using a predefined set of para-
meters defined as the ‘‘base model’’ (see Material and
Methods). From our calculations, we observed that as
effect size increases, there is significantly more power to
detect risk than protective variants as indicated by the
increase in the NCP ratio (Figure 1). This result shows
that for this scenario, where the number of risk and protec-
tive variants are equal and have similar absolute effect
sizes, the difference in power can create an excess of, 2014
Figure 1. Comparing the Power to Detect Risk and Protective
Variants with the Same Underlying Effect Size
The plot shows the power as the noncentrality parameter (NCP)
for detecting minor alleles that confer risk (risk variants) and
minor alleles that confer protection (protective variants) with
varying absolute effect sizes (0 < b < 0.5 in standard deviation
units) via parameters from the base model (see Material and
Methods). It also shows the NCP ratio, which is the NCP of risk
variants divided by the NCP of protective variants with the same
absolute effect size (right vertical axis). The equivalent odds ratio
(OR) for the risk variants is also shown on the horizontal axis.detected risk variants over protective variants, which can
result in an increased R/P ratio.
The Difference in Power Is Larger under Certain
Scenarios
We explored how the difference in power to detect risk and
protective variants would be affected when we varied the
parameters in themodel under which we calculated power.
First, we calculated power via the basemodel but varied the
minor allele frequency from 1% to 15%. The difference in
power for risk and protective variants decreases as the
variant frequency increases (Figure 2A). Second, we varied
the disease prevalence from 1% (trait Z score > 2.33) to
15% (trait Z score > 1.03). Here, the difference in power
decreases with increasing disease prevalence (Figure 2B),
and there is no difference in power at any effect size
when the disease prevalence is exactly 50%. Third, we
varied the linkage disequilibrium (LD) between the asso-
ciated variant and the causal variant from moderate LD
(D0 ¼ 0.5) to strong LD (D0 ¼ 0.8). Although there is a gen-
eral loss of power with decreasing LD, the difference in
power between risk and protective variants increases with
decreasing LD (Figure 2C). Along similar lines, when we
assumed that low-frequency causal variants are being
tagged by variants of higher frequencies (fixing the fre-
quency of the tagged variant at 5% and varying the fre-
quency of the causal variant from 4% to 1%), we alsoThe Ameobserved a greater difference in power as the causal variant
frequency decreased (Figure 2D). These results show that
the difference in power between risk and protective vari-
ants should be more obvious when testing variants within
the low-frequency range (<5% frequency), in polygenic
diseases with lower prevalence, and when the markers
being tested are proxies for lower-frequency causal vari-
ants. The driving force behind this result is that the case
group is ascertained from individuals with an extreme
distribution of liability scores whereas the control group
has a much broader distribution of liability scores. Conse-
quently, given equal sizes of the case and control groups,
the increase in minor allele count of a risk variant in the
case group is greater than the increase in minor allele
count of an equally strong protective variant in the control
group, leading to higher power for detecting the risk
variant (see Appendix A for derived formulae that confirm
the increase in power). Thus, if rare or low-frequency vari-
ants play a substantial role in certain diseases with poly-
genic architecture, these results predict that we could
observe an increased R/P ratio for low-frequency variants
in the GWAS summary statistics for these diseases.
Excess of Risk Variants Can Be Caused by Negative
Selection
Beyond the differences in power, an excess of risk
compared to protective variants can also occur if there is
negative selection against the disease, leading risk variants
to be kept at lower frequencies than protective variants. To
illustrate this scenario, we simulated negative selection
by coupling effects on evolutionary fitness and on a quan-
titative trait for a set of variants (frequencyR 1%) and then
assigning case-control status based on the trait values (see
Material andMethods). We observed an increase in the R/P
ratio for the frequency bins within 1% to 15% but not
for the 30% to 50% frequency bin (Figures 3A and S3).
These results show that under a model where rare variants
contribute to disease and are under negative selection, we
could also observe an increase in the R/P ratio for low-
frequency variants in the GWAS summary statistics for
these diseases.
Excess of Risk Variants Arise from Having More
Control than Case Subjects
The previous results show that polygenic inheritance from
lower-frequency variants can lead to an increase in the R/P
ratio but that such an increase can occur in other settings
as well. Under the null hypothesis, one would expect
that on average, the number of detected risk variants
would be equal to the number of detected protective vari-
ants, resulting in an expected R/P ratio of 1. However, in
our simulations, we observed that the expected R/P ratio
can deviate from 1 because of an imbalance between the
sizes of the case and control groups. Specifically, if there
are substantially more control than case subjects, a feature
present in some GWASs of dichotomous traits, it would
result in the increase of the expected R/P ratio (R/Prican Journal of Human Genetics 94, 437–452, March 6, 2014 441
Figure 2. Effects of Varying Various
Parameters on the NCP Ratio
The plots show the difference in power for
detecting risk versus protective variants
through the NCP ratio under varying
parameters. Unless otherwise specified,
the parameters used for calculating NCP
are from the base model (see Material and
Methods).
(A) Minor allele frequency of the associ-
ated variant varying from 1% to 15%.
(B) Disease prevalence (threshold of liabil-
ity) varying from 1% to 15%.
(C) Linkage disequilibrium (LD) between
the causal variant and the marker variant
as a function of D0 (varying from 0.5
to 0.8).
(D) The marker variant frequency is set at
5% with the causal variant frequency
ranging from 1% to 4%.ratio > 1). To illustrate this, we randomly simulated 1,000
case subjects and 3,000 control subjects (1k/3k) and
measured the distribution of the R/P ratio under a null
model of no association (see Material and Methods). We
observed that there is an increase in the R/P ratio distribu-
tion for 1k/3k for the low-frequency bins (Figures 3B and
S4). This increase is not seen with common variants
(30%–50% frequency bin), nor if the numbers of case
and control subjects are equal (Figures 3B and S4). Of
note, with larger sample sizes (10,000 case subjects and
30,000 control subjects; 10k/30k), we observed that the
increase in R/P ratio is substantially attenuated (Figures
3B and S4). These results show that an excess of control
subjects can increase the expected R/P ratio and should
be accounted for by comparing the observed R/P ratio
against those obtained through simulations under a null
model. These results also show that with sufficiently large
number of case subjects (e.g., >10,000), the increase in the
expected R/P ratio resulting from this imbalance will be
minimal.
Excess of Risk Variants Can Result from Asymmetric
Population Stratification
We also considered whether an excess of risk variants
could be seen in GWASs that are confounded by popula-
tion stratification. As a first test, we randomly simulated
1,000 individuals of either northern European ancestry
(CEU, based on allele frequencies in the CEU HapMap442 The American Journal of Human Genetics 94, 437–452, March 6, 2014sample) or southern European
ancestry (TSI, based on allele fre-
quencies in the TSI HapMap sample).
In one experiment, we simulated
1,000 CEU individuals as control
subjects and 1,000 TSI individuals as
case subjects (see Material and
Methods), and as a stratification-free
experiment, we simulated 1,000
CEU control subjects and 1,000 CEUcase subjects. The simulated TSI and CEU populations
show the expected differences in principal component
analysis (Figure S5). We found that although there was a
large excess of apparent associations for both risk and
protective variants, leading to enormous inflation of the
genomic control test statistic (lGC ~ 22.9), the resulting
R/P ratio did not deviate substantially from expectations
under the null (Figures 3C and S6). Therefore, even
extreme scenarios with the usual forms of population
stratification should not cause substantial deviations of
the R/P ratio.
However, we reasoned that a special case of asymmetric
population stratification could potentially cause the R/P
ratio to depart from expectations under the null. Specif-
ically, if there were a mixture of different populations in
only the case group and not in the control group, or vice
versa, it could lead to an increase or decrease of the R/P
ratio. To test this, we randomly simulated a series ofmodels
where the control group is homogenous (CEU) but the case
group is a mixture of CEU and TSI individuals (see Material
and Methods). At a 1% mixture in the case group (lGC ~
1.01), we did not observe any significant excess of risk
variants, but at 5% mixture (lGC ~ 1.06), we observed an
excess of risk variants within the low-frequency ranges
(Figures 3D and S7). This excess is even larger with a 10%
mixture (lGC ~ 1.24) (Figures 3D and S7). Variants within
the common frequency range do not show an excess of
risk variants (Figures 3D and S7). These results show that
Figure 3. The Distribution of the R/P
Ratio from Simulating Variants under
Various Scenarios
The figure shows the distribution of the
log2 R/P ratio for the 1%–5% and 30%–
50% frequency bins from simulating vari-
ants under various scenarios. The p value
cutoff for each of the bins is 0.01.
(A) Simulating variants under negative
selection. The selection model (red) uses
the 823 effective variants whereas the
control (black) model assumes that no
variants affect the phenotype.
(B) Simulating larger size of control than
case group. The 1k/3k (red) model simu-
lates the null distribution of the log2 R/P
ratio for 1,000 case subjects and 3,000
control subjects. The 10k/30k (orange)
model simulates the null distribution of
the log2 R/P ratio for 10,000 case subjects
and 30,000 control subjects. The control
(black) model simulates the null distribu-
tion of the log2 R/P ratio for 1,000 case sub-
jects and 1,000 control subjects.
(C) Simulating population stratification.
The stratification model (red): case group
simulated from TSI population and control
group simulated from the CEU population.
The control model (black): both case and
control groups simulated from the CEU
population.
(D) Simulating asymmetric population
stratification. The models for asymmetric
population stratification are as follows.
Mixed 10%, 5%, and 1% indicate that
10%, 5%, and 1% of the case group is simu-
lated from TSI individuals, respectively,
and the rest of the individuals used are
simulated from CEU individuals. The con-
trol model is comprised of case subjects
simulated only from CEU individuals, i.e.,
without any population stratification.
(E) Simulating asymmetric population
stratification after meta-analysis with
nonstratified data. The model ‘‘mixed
10%’’ and ‘‘meta analyzed’’ refers to
asymmetric population stratification of
10% mixture of TSI individuals of the
case subjects before and after being meta-
analyzed with four other data sets without
such stratification, respectively. The con-
trol model indicates no asymmetric popu-
lation stratification.such asymmetric population stratification can increase
the R/P ratio, with only moderate increases in the genomic
control statistics. As a corollary, if the mixture were to exist
in the control group but not in the case group, we would
expect the R/P ratio to decrease.
Finally, we meta-analyzed the results from the asymmet-
rically stratified GWASs with results from nonstratified
GWASs (see Material and Methods) to determine the effect
on the R/P ratio if only a subset of the studies had asym-
metric population stratification. We found that the in-
crease in the R/P ratio is attenuated after meta-analysis
(Figures 3E and S8). These results indicate that whereas
asymmetric population stratification can give rise to anThe Ameexcess of risk variants, combining such results with non-
stratified results can reduce the magnitude of the signal.
Because this particular type of stratification is unlikely to
be present in most of the cohorts prior to meta-analysis,
it may be useful to examine the summary statistics
of each study individually to determine whether the
increased R/P ratio is derived from a subset of studies in
the GWAS meta-analysis. Ideally, if an increased R/P
ratio is observed, principal component analysis or other
methods should also be applied to the primary data to
search for outliers present exclusively in the case group
to further rule out asymmetric population stratification
as a cause of an increased R/P ratio.rican Journal of Human Genetics 94, 437–452, March 6, 2014 443
Table 1. Schizophrenia, Major Depressive Disorder, and Bipolar Disorder
Freq (%)
p Value
Cutoff
SCZ MDD BIP
O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p
1–5 0.001 1.864 1.127 0.0298 1.210 1.058 0.269 0.884 1.110 0.748
0.01 1.623 1.032 2.42 3 107* 1.169 1.006 0.048 0.953 1.028 0.778
5–10 0.001 1.348 1.057 0.1279 0.933 1.039 0.623 1.038 1.077 0.509
0.01 1.230 1.019 0.0111 0.914 1.005 0.865 0.973 1.013 0.678
10–15 0.001 1.050 1.082 0.4926 1.348 1.035 0.126 1.038 1.055 0.473
0.01 1.054 1.019 0.3335 1.193 1.005 0.027 1.046 1.015 0.349
30–50 0.001 1.063 1.022 0.3736 1.098 1.003 0.264 1.122 1.039 0.291
0.01 1.001 1.003 0.5010 0.944 1.001 0.836 1.070 1.009 0.165
The observed and expected R/P ratios and p values obtained from analyzing GWAS summary statistics of psychiatric disorders: schizophrenia (SCZ), major depres-
sive disorder (MDD), and bipolar disorder (BIP). O(R/P) refers to the observed R/P ratio and E(R/P) refers to the expected R/P ratio obtained through simulations. p
refers to the p value obtained from a one-tailed Z test (*p < 0.01).Using the R/P Ratio in Actual GWAS Results to Search
for Signals of Low-Frequency Variants Contributing to
Disease Risk
Schizophrenia, Major Depressive Disorder, and Bipolar Disorder
We applied our method to data from several psychiatric
disorders: schizophrenia,11 bipolar disorder,12 and major
depressive disorder.13 We observed a significant increase
in the R/P ratio only for schizophrenia in the 1%–5%
frequency bin, at a cutoff of p < 0.01 (p ¼ 2.42 3 107)
(Table 1). We did not observe any significant differences
in the other frequency bins nor for any of the other psy-
chiatric disorders (Table 1). These results are indicative of
polygenic inheritance from low-frequency variants in
schizophrenia but do not provide similar support for a
role of low-frequency variants in major depressive disorder
or bipolar disorder.
Type 2 Diabetes
Next, we applied our method to GWAS results of type 2
diabetes.14 The R/P ratio for type 2 diabetes was signifi-Table 2. Type 2 Diabetes
Freq (%)
p Value
Cutoff
T2D
O(R/P) E(R/P) p
1–5 0.001 3.833 1.205 5.89 3 106*
0.01 2.009 1.069 3.08 3 1015*
5–10 0.001 1.636 1.131 0.043
0.01 1.439 1.051 2.28 3 105*
10–15 0.001 1.660 1.081 0.031
0.01 1.400 1.033 8.36 3 104*
30–50 0.001 1.041 1.038 0.459
0.01 1.035 1.008 0.308
The observed and expected R/P ratios and p values obtained from analyzing
GWAS summary statistics of type 2 diabetes (T2D). O(R/P) refers to the
observed R/P ratio and E(R/P) refers to the expected R/P ratio obtained
through simulations. p refers to the p value obtained from a one-tailed Z test
(*p < 0.01).
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most significant difference was observed in the 1%–5%
bin with cutoff of p < 0.01 (p ¼ 3.08 3 1015). We also
observed a significant excess of risk variants in the 10%–
15% bin (p< 0.01, p¼ 2.283 105). Because the difference
in power between risk and protective variants becomes
minimal as the variant frequency increases, this observed
excess of risk variants is more probably due to negative
selection on diabetes risk alleles, tagging of low-frequency
variants by the more common SNPs in this frequency
range, and/or possibly asymmetric population stratifi-
cation. Nonetheless, these results are indicative of poly-
genic inheritance from low-frequency variants in type
2 diabetes.
Obesity
We also applied our method to GWAS results for various
classes of obesity:15 overweight (BMI > 25), class 1
(BMI > 30), class 2 (BMI > 35), and class 3 (BMI > 40).
The control group used for each class of obesity were indi-
viduals with BMI < 25. We observed a significant increase
in the 1%–5% frequency bin with a cutoff of p < 0.01 for
only the class 1 data set (p ¼ 8.8 3 106) (Table 3). Also,
although we generally observed a gradual increase in the
R/P ratio with increasing BMI definitions of obesity, which
could be consistent with a role of lower-frequency variants,
the increase in R/P ratio could also be explained by having
a larger control than case group. We did not observe any
significant excess of risk variants for the low-frequency
bins in the class 2 or class 3 data sets, probably because
of the severely reduced sample sizes for the more extreme
BMI definitions of obesity.Testing whether Related Phenotypes Are Likely to
Share Low-Frequency Causal Variants
To increase the power of GWASs, some studies have
pooled apparently related phenotypes into a single case
group.16,17 We applied our method to measure the R/P
ratio on published GWAS results of these related, 2014
Table 3. Obesity
Freq (%)
p Value
Cutoff
Overweight Class 1 Class 2 Class 3
O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p
1–5 0.001 1.188 0.997 0.228 0.917 1.164 0.758 2.462 2.410 0.410 3.700 3.454 0.354
0.01 1.120 0.986 0.078 1.536 1.050 8.8 3 106* 1.533 1.376 0.114 1.814 1.617 0.111
5–10 0.001 1.026 0.998 0.408 1.139 1.098 0.393 0.697 1.640 0.999 1.857 2.067 0.607
0.01 1.023 0.991 0.328 0.937 1.023 0.838 1.108 1.222 0.871 1.227 1.346 0.845
10–15 0.001 0.784 0.999 0.826 0.971 1.087 0.610 1.276 1.567 0.713 1.385 1.766 0.779
0.01 1.109 1.003 0.113 1.013 1.028 0.544 1.066 1.208 0.883 1.269 1.267 0.479
30–50 0.001 1.121 0.991 0.194 1.059 1.020 0.380 0.949 1.094 0.763 1.019 1.112 0.696
0.01 1.022 0.999 0.340 1.045 1.004 0.225 0.985 1.035 0.816 0.955 1.044 0.946
The observed and expected R/P ratios and p values obtained from analyzing GWAS summary statistics of clinical classes of obesity: overweight (BMI > 25), class 1
(BMI > 30), class 2 (BMI > 35), and class 3 (BMI > 40). O(R/P) refers to the observed R/P ratio and E(R/P) refers to the expected R/P ratio obtained through
simulations. p refers to the p value obtained from a one-tailed Z test (*p < 0.01).phenotypes. We reasoned that our method could also be
used to test whether pooling related phenotypes would
increase power to detect low-frequency variants, using
only the GWAS summary statistics. We applied our
method to GWAS results from two different pairs of related
phenotypes, one pair for inflammatory bowel disease and
one pair for diabetic nephropathy.
Inflammatory Bowel Disease
The two major types of inflammatory bowel disease are
Crohn disease (CD) and ulcerative colitis (UC).36We exam-
ined the R/P ratio in GWAS results for Crohn disease,32
ulcerative colitis,33 and the combined case cohort of both
Crohn disease and ulcerative colitis.17 We observed signif-
icant increases in the R/P ratio for both Crohn disease and
ulcerative colitis within the low-frequency bins (Table 4).
The most significant increases were found in the 1%–5%
bin with cutoff of p < 0.01 (CD, p ¼ 1.55 3 1010; UC,
p ¼ 2.25 3 109), consistent with a polygenic role of
low-frequency variants in both diseases. However, when
Crohn disease and ulcerative colitis were combined as a
single case group (CD þ UC), the increase in R/P ratio is
less significant than in the individual GWAS results
(Table 4). These results suggest that there are some low-
frequency genetic contributors to Crohn disease and ulcer-
ative colitis that are not shared by both diseases. However,
because the signal is still present (albeit attenuated) when
both diseases were studied together, it also suggests that
the two diseases do share some overlapping low-frequency
genetic contributors, although the attenuated signal could
reflect persistence of two separate individual signals that
are diluted after combination of the two sets of cases.
Diabetic Nephropathy
We performed a similar analysis on two phenotypes used
to characterize diabetic nephropathy:18 macroalbuminuria
(MACRO) and end-stage renal disease (ESRD). Unlike in-
flammatory bowel disease, MACRO and ESRD are not
necessarily distinct; MACRO is a milder form of diabetic
nephropathy and some of the individuals thus affectedThe Ameprogress to develop ESRD. The control group used for
that study were diabetic individuals that did not develop
nephropathy. We analyzed the GWAS results performed
for individuals with macroalbuminuria versus control
subjects (MACROctrl), individuals with end-stage renal
disease versus control subjects (ESRDctrl), individuals
with end-stage renal disease versus control subjects
that also include individuals with macroalbuminuria
(ESRDctrlþmacro), and a combined case cohort that includes
both individuals with macroalbuminuria and end-stage
renal disease versus control subjects ([MACROþ ESRD]ctrl).
For the analyses of MACROctrl and of ESRDctrl, we observed
significant increases to the R/P ratio in the 1%–5% bin
with cutoff of p < 0.01 (MACROctrl, p ¼ 0.001; ESRDctrl,
p ¼ 6.4 3 105) (Table 5). For the ESRDctrlþmacro analysis,
where individuals with macroalbuminuria are included
within the control group, there is an even larger increase
of the R/P ratio (ESRDctrlþmacro, p ¼ 9 3 1011) (Table 5).
However, when MACROctrl and ESRDctrl were combined
into a single case group ([MACRO þ ESRD]ctrl), none of
the frequency bins showed significant increases in the
R/P ratio (Table 5). These results suggest that although
there are low-frequency contributors to both macro-
albuminuria and end-stage renal disease, these contribu-
tors do not substantially overlap. There is no detectable
increase in the R/P ratio when both phenotypes are com-
bined, unlike our observations for inflammatory bowel
disease. Thus, these results indicate that studies of low-
frequency variation for diabetic nephropathy would be
more fruitful if MACRO and ESRD are tested separately.Discussion
We have shown that our method for measuring the R/P
ratio can be used as a test for the presence of multiple
low-frequency or rare genetic contributors to disease risk.
This method can be applied to GWAS summary statistics,rican Journal of Human Genetics 94, 437–452, March 6, 2014 445
Table 4. Inflammatory Bowel Disease: Crohn Disease and Ulcerative Colitis
Freq (%)
p Value
Cutoff
CD UC CDþUC
O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p
1–5 0.001 2.545 1.347 0.017 1.958 1.358 0.075 1.385 1.159 0.222
0.01 1.994 1.111 1.55 3 1010* 1.866 1.106 2.25 3 109* 1.457 1.048 1.6 3 104*
5–10 0.001 1.148 1.162 0.477 1.490 1.192 0.153 1.099 1.107 0.463
0.01 1.314 1.069 1.4 3 103* 1.460 1.066 8.59 3 105* 1.239 1.027 0.012
10–15 0.001 1.200 1.181 0.424 1.279 1.186 0.337 1.583 1.076 0.059
0.01 1.043 1.059 0.551 1.213 1.066 0.075 1.104 1.026 0.205
30–50 0.001 0.925 1.035 0.743 1.163 1.037 0.217 1.036 1.026 0.445
0.01 1.052 1.018 0.266 1.004 1.009 0.524 1.043 1.005 0.251
The observed and expected R/P ratios and p values obtained from analyzing GWAS summary statistics of inflammatory bowel diseases: Crohn disease (CD),
ulcerative colitis (UC), and the combined CD and UC as a single case group (CDþUC). O(R/P) refers to the observed R/P ratio and E(R/P) refers to the expected
R/P ratio obtained through simulations. p refers to the p value obtained from a one-tailed Z test (*p < 0.01).even if there are few or no genome-wide significant asso-
ciations. We analyzed results from multiple published
GWASs and found significant signals in some but not all
diseases. These results support the hypothesis that the
diseases where the R/P ratio is increased have a polygenic
contribution from as-yet-undetected low-frequency or
rare variants.
Some existing methods for detecting polygenic inheri-
tance9,10,37 use variants that achieve nominal significance
in GWASs to determine whether they are informative as
predictors of phenotype. Because our method assesses
the direction of effect of these variants against the null
model, our method represents a rather different, indepen-
dent approach for assessing polygenic inheritance of low-
frequency variants. Furthermore, our method does not
require having identified associated loci or the availability
of individual level data. For example, in schizophrenia, it
has been shown that a substantial proportion of schizo-
phrenia disease risk is the result of variants with fre-
quency >1%.38 Our finding suggests that some disease
risk is accounted for by variants within the low-frequency
range (frequency < 5%). In a recent exome-sequencing
study of 2,536 schizophrenia cases and 2,543 controls,39
Purcell and colleagues showed a polygenic burden of
rare disruptive mutations, which is consistent with our
observation. Similarly, for type 2 diabetes, our results
suggest the presence of low-frequency or rare variants
contributing to disease risk, even though most of the var-
iants known to be associated with disease risk are com-
mon (frequency R 5%).14
We also showed that negative selection under polygenic
inheritance can increase the R/P ratio for low-frequency
variants, because risk variants would be kept at lower
frequencies while the protective variants could drift
to higher frequencies. Indeed, in a previous study,40
Park and colleagues showed that across most qualitative
traits, minor alleles conferred risk more often than pro-
tection, which they concluded to be evidence for purifying446 The American Journal of Human Genetics 94, 437–452, March 6selection. Although this can be the case for some diseases,
we showed that this increase in the R/P ratio can also arise
because there is more power to detect risk variants than to
detect protective variants. Furthermore, we have estab-
lished that if there are substantially more control than
case subjects, a feature present inmany GWASs, this imbal-
ance can distort the null distribution such that there would
appear to be more risk than protective variants. However,
this imbalance can be accounted for through simulations,
as we have demonstrated.
Our method also provides a simple and early way of
assessing the utility of different phenotype definitions for
genetic studies of low-frequency variation simply from
GWAS summary statistics. Our results for inflammatory
bowel disease are consistent with the idea that Crohn dis-
ease and ulcerative colitis have some overlapping genetic
contributors. Indeed, a previous study exploring the effect
of common Crohn disease variants on ulcerative colitis
identified significant overlaps between the two diseases,
but also loci specific to Crohn disease.41 For diabetic
nephropathy, where there are few established loci from
which to draw conclusions, we observed signals for both
macroalbuminuria and particularly for end-stage renal dis-
ease when analyzed separately, but no significant signal
when both diseases were combined as a single case group.
This suggests that macroalbuminuria and end-stage renal
disease are distinct in their genetic architecture and would
be more productive if they were to be studied separately.
Interestingly, the same GWAS on diabetic nephropathy
discovered a single genome-wide significant locus only
when end-stage renal disease was treated separately from
macroalbuminuria,16 consistent with our observation.
Finally, asymmetric population stratification between
the case and control groups can lead to both false-positive
associations (as evidenced by an increased genomic con-
trol inflation factor)42 and also an increase in the R/P
ratio. Thus, although our observations of higher-than-
expected R/P ratios in some of the published GWAS data, 2014
Table 5. Diabetic Nephropathy: Macroalbuminuria and End-Stage Renal Disease
Freq (%)
p Value
Cutoff
MACROctrl ESRDctrl ESRDctrlþmacro [MACRO þ ESRD]ctrl
O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p O(R/P) E(R/P) p
1–5 0.001 2.000 1.655 0.205 1.944 1.706 0.283 2.667 2.008 0.146 1.087 1.133 0.504
0.01 1.560 1.198 1.4 3 103* 1.705 1.207 6.4 3 105* 2.270 1.285 9 3 1011* 1.026 1.042 0.550
5–10 0.001 1.563 1.359 0.253 1.278 1.404 0.585 1.533 1.584 0.496 0.875 1.071 0.754
0.01 1.200 1.116 0.175 1.240 1.143 0.147 1.552 1.187 2.9 3 104* 1.045 1.017 0.352
10–15 0.001 0.893 1.275 0.892 1.343 1.304 0.403 1.462 1.397 0.380 0.912 1.038 0.640
0.01 1.208 1.104 0.150 1.190 1.128 0.258 1.310 1.160 0.078 1.053 1.009 0.290
30–50 0.001 1.122 1.066 0.343 1.198 1.051 0.197 0.968 1.076 0.719 1.037 1.001 0.382
0.01 0.990 1.023 0.690 1.152 1.014 0.017 1.038 1.032 0.449 0.981 1.003 0.652
The observed and expected R/P ratios and p values obtained from analyzing GWAS summary statistics of diabetic nephropathy: macroalbuminuria (MACROctrls),
end-stage renal disease (ESRDctrls), ESRD versus controls that include MACRO (ESRDctrlsþmacro), and the combined MACRO and ESRD as a single case group
([MACRO þ ESRD]ctrls). O(R/P) refers to the observed R/P ratio and E(R/P) refers to the expected R/P ratio obtained through simulations. p refers to the p value
obtained from a one-tailed Z-test (*p < 0.01).sets are suggestive of a role of low-frequency variants, we
cannot completely rule out that some of these signals
could be in part explained by asymmetric population strat-
ification. Of note, none of the R/P ratios showed a deficit of
risk variants (which would be expected under somemodels
of asymmetric population stratification), suggesting that
asymmetric population stratification is not widespread.
Furthermore, these GWASs have used methods to detect
and correct for population stratification.
In conclusion, our method can be used to screen for
polygenic inheritance from low-frequency or rare variants
in diseases where GWASs have been performed. Our
method can also be extended to other summary statistics,
e.g., studies from sequencing or exome-chip genotyping,
to assess low-frequency variants that were directly geno-
typed rather than imputed. This method can serve as a
simple approach to guide researchers in prioritizing strate-
gies in searching for as-yet-unexplained heritability for
specific diseases. For example, in a study of epilepsy,43
Heinzen and colleagues failed to identify any rare variants
of large effect through exome sequencing; analysis of
GWAS data for epilepsy can in theory help guide decisions
about embarking on additional studies of low-frequency or
rare variants with larger sample sizes. Although a lack of a
signal from our method does not rule out a role for low-fre-
quency variants and may reflect a combination of small
sample sizes and a set of effect sizes and frequencies that
do not significantly alter the R/P ratio, a positive signal
can provide greater confidence about the likelihood that
low-frequency or rare variants contribute to disease risk.Appendix A
Calculating NCP from Various Given Parameters
We define the following parameters required to calculate
the noncentrality parameter (NCP) as a function of effectThe Amesize of minor allele (b), minor allele frequency (p), liability
threshold (t), number of case individuals (Nd), and
number of control individuals (Nc). We denote the minor
allele (effect allele) as a1 and the major allele (noneffect
allele) as a2. As such, the liability distribution of a1 is N(x,
m1, s
2) and the liability distribution of a2 is N(x, m2, s
2)
such that N(x, m,s2) is the probability density function of
a normal distribution with mean m and variance s2.
The mean liabilities for a1 and a2 are as follows:
Mean liability for a1 ¼ m1 ¼ b bp ¼ bq
Mean liability for a2 ¼ m2 ¼ bp
where q is the major allele frequency such that p þ q ¼ 1.
The variance remaining s2 is:
Variance remaining ¼ s2 ¼ 1 b2pq:
Next, we calculate a series of conditional probabilities
as follows:
Pðcase j a1Þ ¼
ZN
t
N

x;m1;s
2

dx
Pðcase j a2Þ ¼
ZN
t
N

x;m2;s
2

dx
Pðcontrol j a1Þ ¼
Z t
N
N

x;m1;s
2

dx
Pðcontrol j a2Þ ¼
Z t
N
N

x;m2;s
2

dx:
With these conditional probabilities, we proceed to
calculate the expected allele frequencies of both therican Journal of Human Genetics 94, 437–452, March 6, 2014 447
minor allele and major allele in both case subjects and
control subjects by using Bayes’ theorem. These are calcu-
lated as:
Pd1 ¼ Pða1 j caseÞ ¼ Pðcase j a1ÞpZ N
t
Nðx;0;1Þdx
Pd2 ¼ Pða2 j caseÞ ¼ 1 Pd1
Pc1 ¼ Pða1 j controlÞ ¼ Pðcontrol j a1ÞpZ t
N
Nðx;0;1Þdx
Pc2 ¼ Pða2 j controlÞ ¼ 1 Pc1:
We then calculate the NCP by the c2 statistic from a 2
by 2 contingency table for the expectation of the
observed number of a1 and a2 in both the case and control
groups.Case Control Total
a1 2 Nd Pd1 2 Nc Pc1 2 A
a2 2 Nd (1- Pd1) 2 Nc (1- Pc1) 2 B
Total 2 Nd 2 Nc 2 Twhere
A ¼ Nd Pd1 þNc Pc1
B ¼ Ndð1 Pd1Þ þNcð1 Pc1Þ
T ¼ Aþ B ¼ Nd þNc:
The expected number for each cell is the row total times
the column total divided by the grand total.
Thus, the NCP is calculated as:
NCP ¼
X
Each cell
ðObserved  ExpectedÞ2
Expected
NCP ¼

2Nd Pd1  4ANd
2T
2
4ANd
2T
þ

2NcPc1  4ANc
2T
2
4ANc
2T
þ

2NdPd2  4BNd
2T
2
4BNd
2T
þ

2NcPc2  4BNc
2T
2
4BNc
2T
NCP ¼ 2TNdP
2
d1
A
þ 2ANd
T
 4NdPd1 þ 2TNcP
2
c1
A
þ 2ANc
T
4NcPc1 þ 2TNdð1 Pd1Þ
2
B
þ 2BNd
T
 4Ndð1 Pd1Þ
þ2TNcð1 Pc1Þ
2
B
þ 2BNc
T
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2
d1 2TNcP
2
c1 2TNdð1 Pd1Þ2NCP ¼
A
þ
A
þ
B
þ 2TNcð1 Pc1Þ
2
B
 2T :
After some algebra and simplification,
NCP ¼ 2T
AB
NdNcðPd1  Pc1Þ2:
Therefore,
NCP ¼ 2NdNcðPd1  Pc1Þ2

Nd þNc
ðNdPd1 þNcPc1ÞðNdPd2 þNcPc2Þ

:
We verified that these formulae were correct by comparing
to simulated results.Determining NCP Ratio between Risk and Protective
Variants with the Same Magnitude of Effect
We formulated the various probabilities between risk and
protective variants. Assuming b to be positive, the risk
variant would have the following probabilities:
Pd1 ¼
p
Z N
t
N

x; bq;s2

dxZ N
t
Nðx;0;1Þdx
Pc1 ¼
p
Z t
N
N

x; bq;s2

dxZ t
N
Nðx;0; 1Þdx
and the protective variant with the same magnitude of
effect would have the following probabilities:
Pd1 ¼
p
Z N
t
N

x;bq;s2dxZ N
t
Nðx;0;1Þdx
Pc1 ¼
p
Z t
N
N

x;bq;s2dxZ t
N
Nðx;0;1Þdx
:
Assuming that there are equal number of case and
control subjects (N1 ¼ N2), then
NCP a
0
BBB@
Z N
t
N

x; bq;s2

dxZ N
t
Nðx;0;1Þdx

Z t
N
N

x; bq;s2

dxZ t
N
Nðx;0;1Þdx
1
CCCA
2
:
The ratio between risk and protective variants with the
similar magnitude of b is therefore, 2014
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When prevalence is 50% (t¼0),
Z0
bq
s
Nðz;0;1Þdz ¼
Zþbqs
0
Nðy;0; 1Þdy:
and therefore
NCP ratio ¼ 1:
This shows that when prevalence is 50% (t ¼ 0) and
there are equal sample numbers in the case and control
groups (N1 ¼ N2), the NCP between risk and protective
variants with identical magnitudes of effect (b) would be
the same regardless of any other parameters.
For the case where t > 0, if
Z t
tbq
s
Nðz;0;1Þdz
Ztþbqs
t
Nðy;0;1Þdy > 0;then the NCP for risk variants will be greater than the
NCP for protective variants and the NCP ratio will be
greater than 1. When t > bq, this will be true because
the normal distribution is monotonic decreasing above
z ¼ 0 (y ¼ 0).
To extend this to the more general case of t > 0, we first
examine the individual components,rican Journal of Human Genetics 94, 437–452, March 6, 2014 449
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Taking the first two terms of the Taylor-series expansion
of the error function and approximating s to 1 (sz 1),
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As such, if t > 0,1ﬃﬃﬃ
p
p
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> 0:
Therefore, if t > 0,Z t
tbq
s
Nðz;0;1Þdz >
Ztþbqs
t
Nðy; 0;1Þdy
NCP ratio > 1:
Therefore, for diseases with low prevalence (t > 0), there is
more power to detect risk variants compared with the pro-
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